Myeloma Minute: We Will Get Through This Together


| INNOVATION | Latest Research


We Will Get Through This Together: The New Normal

This week, in our coverage of the COVID-19 pandemic, IMF Chairman Dr. Brian G.M. Durie shares the latest findings on the virus’s impact on myeloma patients, offers suggestions for coping with the new normal, and finds inspiration in unexpected places for staying resilient during these challenging times.


| EDUCATION | Webinar


Join This Webinar on Multiple Myeloma Patient Safety and the Coronavirus

The next “Living Well with Myeloma” webinar takes place on Thursday, April 16, at 1:00 p.m. PT / 2:00 p.m. MT / 3:00 p.m. CT / 4:00 p.m. ET. The panel includes myeloma experts Paul Richardson, MD; Brian G.M. Durie, MD; and Beth Faiman, PhD, RN. They share the latest updates, insights, and resources to keep myeloma patients safe during the coronavirus (COVID-19) pandemic. There will be an opportunity to ask questions to the panel as well during this webinar.

Register Now Button.png

| INSPIRATION | Virtual Race


| ACTION | Ways to Give


Schedule a Private Run/Walk from Any Location for This Year’s Miles for Myeloma!
Shop Amazon and Give to the IMF, with No Added Cost to You!

The Miles for Myeloma 5K Run/Walk is NOW VIRTUAL! The race usually takes place in Philadelphia, but now anyone anywhere in the world can participate! Visit the link below to learn about this new and exciting style of racing.

Online shopping while social distancing? Did you know if you visit and choose the International Myeloma Foundation as your preferred charity, Amazon will give a percentage of your purchase to the IMF? It’s all at no added cost to you!



| INNOVATION | Clinical Trial


Low Dose Selinexor To Be Evaluated as Possible Treatment for Patients Hospitalized with COVID-19

Karyopharm Therapeutics Inc. announced “plans to initiate a global randomized clinical trial for low dose oral selinexor in hospitalized patients with severe COVID-19. Selinexor, marketed as XPOVIO®, is currently approved at higher doses by the Food and Drug Administration (FDA) as a treatment for patients with relapsed or refractory multiple myeloma. Selinexor is an oral, selective inhibitor of nuclear export (SINE) compound which blocks the cellular protein XPO1.” Furthermore, “SINE compounds have recently been identified as having the potential to interfere with key host protein interactions with SARS-CoV-2, the virus that causes COVID-19.” Selinexor is the “the only XPO1 inhibitor approved for commercial use by the FDA and has been extensively tested in clinical trials across numerous cancer indications worldwide since 2012. The proposed clinical trial to treat hospitalized patients with COVID-19 would be the first study of an XPO1 inhibitor in patients with severe viral infections.”


| ACTION | Advocacy Alert


Ensure Myeloma Patients Do Not Face Treatment Discrimination During the COVID-19 Pandemic

Cancer patients are facing unique challenges during the COVID-19 pandemic, and IMF’s Advocacy team has been working hard to address these issues with lawmakers. There has been a lot of talk about triaging care during the pandemic, and we have concerns a myeloma diagnosis could preclude a patient from receiving lifesaving treatment for COVID-19 without examining their overall health.

To ensure cancer patients are not discriminated against during the triage process, contact your legislator at the link below.


| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series



Search the Myeloma Matrix 2.0

Join the conversation about myeloma on the Smart Patients Message Board

Clinical Trial Fact Sheets

OCEAN Trial (Now Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Hawaiian Vacation Raffle
Kailua-Kona, Hawaii

Hatfield Hike
Appalachian Trail

April 25, 2020
VIRTUAL Miles for Myeloma 5K Run/Walk

subscribe_button.png     donate_button_bottom.png
We Thank Our Sponsors:
Amgen, Bristol-Myers Squibb, Genentech, GSK, Sanofi-Genzyme, and Takeda Oncology

We also thank individuals like you for your continued support!

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.